How to buy Cognizant (CTSH) stock from India

Yes, an Indian resident can buy Cognizant — legally, in US dollars, under the RBI's LRS. Cognizant is unusual: with 250,000-plus India-based employees, many readers already hold CTSH via RSUs or ESPP. The buying is the easy 10%. The 90% is concentration risk, dividend tax, estate-tax exposure, and position sizing.

The 30-second version

• Legal and simple. Buy CTSH via Vested, INDmoney, Interactive Brokers, or Rovia. Whole shares or a fractional rupee amount.
• Dividend-paying name. CTSH pays a quarterly dividend. The US withholds 25% under the India-US DTAA with a valid W-8BEN; you claim the credit in India via Form 67.
• India tax on gains: hold more than 24 months and pay 12.5% LTCG (no indexation); sell sooner and pay your slab rate. Section 112, not the friendlier 112A that Indian shares get.
• If you already work at Cognizant, your salary, bonus, and RSUs are all tied to one employer — more CTSH on top is a real concentration risk.
• The trap most miss: directly-held CTSH is a US-situs asset — above $60,000, your estate faces up to 40% US estate tax, with no treaty relief.
• If your thesis is "US IT services," VTI and VOO already hold CTSH; XLK gives broader tech exposure.

Quick facts

Can an Indian resident buy it?	Yes — fully legal under the LRS
Ticker / exchange	CTSH / Nasdaq
How	India-facing platform (Vested, INDmoney) or global broker (IBKR, Rovia)
Minimum	A fraction of one share (fractional lets you invest an exact rupee amount)
Dividend	Yes — quarterly; 25% US withholding under DTAA with W-8BEN
India tax on gains	12.5% LTCG after 24 months; else your slab (Section 112)
Estate-tax risk	US-situs above $60k means up to 40%, no treaty relief
Annual compliance	Schedule FA disclosure, Form 67 for the dividend credit, every year you hold

If you already hold CTSH via RSUs or ESPP — read this first

With 250,000-plus India associates, a meaningful share of CTSH's float is held by people whose salary depends on the same company.

• The concentration problem. Your salary, bonus, vesting RSUs, and ESPP are already a leveraged bet on Cognizant. Adding more CTSH on the open market concentrates employer risk in a way no planner would design — a revenue miss hits your stock, your bonus pool, and hiring posture at once.
• Sell-to-cover mechanics. RSUs vest as ordinary income; the broker sells a portion to cover tax, the rest lands in your US brokerage. Treat each vest as a cash-equivalent event — evaluate as if Cognizant paid you cash and you then chose to buy CTSH. Most would not.
• Redeploying proceeds via the LRS. USD proceeds from vested-share sales can be repatriated and reinvested in a diversified portfolio — broad US ETFs, Indian equity, or debt. The mechanics are simple; people fail by not planning the redeployment.

See the complete RSU guide for Indians at US multinationals, should you sell RSUs at vest or hold, and ESPP vs RSU in total comp.

How to buy it — 3 steps

1. Open an account and finish KYC. Pick an India-facing platform (Vested, INDmoney) or a global broker (Interactive Brokers, Rovia). File your W-8BEN during onboarding — this gets you the 25% DTAA rate on Cognizant's dividend instead of the 30% non-treaty default. New to this? Start with how to invest in US stocks from India.
2. Fund it via the LRS. Remit under the LRS (cap: $250,000 per financial year). 20% TCS applies above ten lakh rupees in a year — a creditable prepayment, not a cost. See LRS explained and the LRS and TCS calculator.
3. Place the order. One CTSH share trades in the $70-85 range, so a whole share is affordable, or buy a fractional rupee amount.

The tax that actually matters

Cognizant pays a dividend, so you have two tax events — annual dividend tax and capital-gains tax on exit. Dividends: the US withholds 25% under the India-US treaty (with W-8BEN on file). The same dividend is taxable in India at your slab, and you claim the 25% as a foreign tax credit via Form 67, filed before your ITR. See dividend withholding and Form 67. Capital gains sit under Section 112 — foreign shares don't get the friendlier Section 112A treatment Indian-listed equity enjoys:

Holding period	Treatment	Rate
24 months or less	Short-term	Your slab rate (up to roughly 30% plus surcharge)
More than 24 months	Long-term	12.5%, no indexation

Worked example. Buy 20 shares at $75 when USD/INR is 86 → cost 1,29,000 rupees. Sell 26 months later at $82 when USD/INR is 88 → proceeds 1,44,320 rupees. Taxable gain 15,320 rupees; LTCG at 12.5% = 1,915 rupees. The gain is computed in rupees, so a weaker rupee amplifies the gain. Model your own with the US capital-gains calculator; full rules in how US stocks are taxed in India.

The $60,000 estate-tax trap

Directly-held CTSH is a US-situs asset. If the holder dies with more than $60,000 of US-situs assets, the estate faces US estate tax up to 40% — the India-US treaty does not cover estate tax, so there is no relief. This is especially relevant for senior Cognizant employees with large accumulated RSU positions; a stack of vested shares can quietly cross the $60k threshold years before anyone notices. The fix — holding US exposure through pooled or fund structures — has to be a deliberate choice made before the position gets large. Full detail: the $60,000 estate-tax trap.

Buy the stock, or get Cognizant through an ETF?

If you want…	Best route
A concentrated bet that CTSH outpaces Accenture, TCS, Infosys	CTSH directly
"US large-cap" exposure with CTSH inside it	VOO or VTI
Broader US technology exposure	XLK or a tech-tilted ETF
The least single-stock and employer-concentration risk	A broad ETF, not more CTSH

Cognizant is a constituent of VTI and VOO, so a broad index already gives you CTSH exposure proportional to its size — plus thousands of other names, one Schedule FA entry, and cleaner estate-tax treatment via pooled vehicles. For a tech tilt, XLK gives sector exposure without single-name risk. Compare in direct stocks vs US ETFs and best US ETFs for Indian investors; the broader case is in US ETFs for Indians.

The business in one screen

What it is: A US-headquartered IT services business with an India-centred delivery base. CEO Ravi Kumar, appointed early 2023, has re-accelerated growth, built specialist verticals via Belcan (engineering) and Thirdera (ServiceNow), and packaged gen-AI via Neuro. Q4 2024 into 2025 showed the first real re-acceleration, though CTSH still trails Accenture, TCS, and Infosys on momentum.

Bull case	Bear case
Gen-AI Neuro pipeline building, larger deal sizes	IT-services growth headwinds — gen-AI deflation, client cost-out
Belcan and Thirdera acquisitions building specialist verticals	Accenture, TCS, Infosys continuing to take share
Sustained buyback and dividend support the floor	Talent attrition and senior-leadership churn risk
India cost base is a structural margin advantage	US visa friction and onshore-cost pressure
Ravi Kumar turnaround narrative is real	USD revenue, INR cost base — a strong rupee is a margin headwind

Exact valuation is in the live widget above — a slow-burn turnaround priced in mid-teens earnings multiples.

Our take

Verdict: HOLD — the turnaround is real but Cognizant remains a price-taker in commodified IT services, with bigger and faster peers eating share.

• The turnaround is real, but unfinished. Ravi Kumar has stabilised growth, sharpened the gen-AI story via Neuro, and added specialist depth through Belcan and Thirdera. But Accenture, TCS, and Infosys are still growing faster, and Cognizant has yet to show it can lead rather than follow.
• Cushion, not catalyst. A consistent dividend, an active buyback, and a low-teens earnings multiple put a floor under the stock. That is a HOLD, not a BUY — upside is capped by the same structural headwinds pressuring the whole sector.
• For Indian RSU holders, the default is to diversify. If Cognizant is your employer, your salary, bonus, and unvested RSUs are already a large bet on CTSH. HOLD what you have, but think hard before adding.

Compliance note. Vested.blog is not a SEBI-registered Research Analyst. The above is an editorial opinion for educational illustration only — not investment advice and not a regulated stock recommendation. Vested.blog is published by Rovia; the publisher and its affiliates may hold positions in stocks discussed. Make your own decisions or consult a SEBI-registered advisor.

Risks to size for

• AI-driven demand compression: gen-AI is deflationary for parts of the IT-services book — if clients do more with smaller vendor budgets, the sector compresses, and Cognizant is not the most differentiated player in it.
• Client concentration and visa friction: large BFSI and healthcare clients dominate the book; US visa policy and onshore-cost pressure can squeeze margins independent of demand.
• Currency: Cognizant bills in USD but pays most of its workforce in INR — a strong rupee is a direct margin headwind. Your own return is also USD against rupee spending; see the rupee-dollar effect.

Two things people forget

• Schedule FA and Form 67: disclose CTSH in Schedule FA every year you hold it — even if bought and sold within the year, even at a loss. Non-disclosure carries Black Money Act penalties. File Form 67 before your ITR to claim the 25% dividend-withholding credit. Use the Schedule FA helper.
• Position size — especially if you work there: a single IT-services name is not an index. If Cognizant pays your salary, your effective CTSH exposure is already enormous before you buy a single open-market share.

Bottom line

Buying CTSH from India is easy and legal. What needs thought isn't the buying — it's that CTSH is a Section-112 capital-gains play with a 25% dividend-withholding line, a US-situs asset with a $60k estate-tax trap, and for the many Cognizant employees reading this, an employer-concentration question first and a stock-picking question second. The Ravi Kumar turnaround is real but unfinished; the dividend and buyback cushion downside without much upside. If your real thesis is "US IT services," a broad ETF gives the same exposure without the single-name and single-employer risk. For accounts and options, start at the US investing hub.

---

This article is general information, not personalised investment, tax, or legal advice. Rules, rates, and thresholds described here are as of 2026 and can change; verify the current position and consult a qualified advisor before acting.